UCLA researchers report erlotinib, an FDA approved drug, reduces glucose uptake in glioblastoma, effectively cutting off nutrients and energy supply to the tumor.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
